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Objectives – Asymmetric dimethylarginine (ADMA) is a nitric oxide synthase (NOS) inhibitor 
and cardiovascular risk factor associated with angiogenic disorders. Enzymes metabolising 
ADMA, dimethylarginine dimethylaminohydrolases (DDAH) promote angiogenesis, but the 
mechanisms are not clear. We hypothesized that ADMA/DDAH modifies endothelial responses to 
vascular endothelial growth factor (VEGF) by affecting activity of Rho GTPases, regulators of 
actin polymerization and focal adhesion dynamics. Methods and Results – The effects of ADMA 
on VEGF-induced endothelial cell motility, focal adhesion turnover and angiogenesis were studied 
in human umbilical vein endothelial cells (HUVECs) and DDAH I heterozygous knockout mice. 
ADMA inhibited VEGF-induced chemotaxis in vitro and angiogenesis in vitro and in vivo in a 
NO-dependent way.  ADMA effects were prevented by overexpression of DDAH, but were not 
associated with decreased proliferation, increased apoptosis or changes in VEGFR-2 activity or 
expression. ADMA inhibited endothelial cell polarisation, protrusion formation and decreased 
focal adhesion dynamics, resulting from Rac1 inhibition following decrease in phosphorylation of 
vasodilator stimulated phosphoprotein (VASP). Constitutively active Rac1 and, to a lesser extent 
dominant negative RhoA abrogated ADMA effects in vitro and in vivo. Conclusion - The 
DDAH/ADMA pathway regulates VEGF-induced angiogenesis in a NO- and Rac1 dependent 
manner.  
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Condensed Abstract: The endogenous NO synthase inhibitor and cardiovascular risk factor 
ADMA, inhibits angiogenesis. We show for the first time, that ADMA inhibits VEGF-induced 
endothelial cell motility and angiogenesis by modulating NO-dependent Rho GTPase activity. 
Further, normal angiogenic responses to VEGF are restored by over-expression of DDAH or 
active Rac1.  
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High plasma levels of ADMA are associated with cardiovascular disorders including 
atherosclerosis, hypertension, homocysteinemia, diabetes mellitus, insulin resistance and 
hypercholesterolemia.1,2 ADMA and the related methylarginine analogue monomethylarginine (L-
NMMA) inhibit NO production by competing with L-arginine for binding to NOS.2 Levels of 
methylarginines are regulated by the enzymes DDAH I and II, which metabolise these factors.2 
DDAH I heterozygote (HT) knockout mice have raised ADMA levels and a hypertensive 
phenotype as a consequence of reduced NO signalling.3 Further, dysregulation of the 
ADMA/DDAH pathway is associated with impaired angiogenesis, which contributes to disease 
pathology. In a mouse model of hypercholesterolemia, DDAH I activity is inhibited by lipid-
induced oxidative stress, leading to elevated ADMA levels, reduced NO production and impaired 
angiogenesis.4 ADMA metabolism through DDAH over-expression promotes angiogenesis in 
vitro,5,6 promotes sprouting from aortic rings,7,8 and enhances angiogenesis in tumours and  
following ischemia6,9 but the mechanisms are not fully understood. 
  ADMA/DDAH pathway may influence angiogenesis by affecting expression of vascular 
endothelial growth factor (VEGF). DDAH over-expression enhances VEGF expression in C6 
glioma cells6 and in human and murine endothelial cell lines.5 ADMA/DDAH may also influence 
VEGF responses by affecting NO bioavailability. NO signalling is critically involved in VEGF-
mediated chemotaxis and angiogenesis.10,11 NO production is increased through a mechanism 
requiring VEGFR-2 activation, which may also involve upregulation of eNOS, increased cytosolic 
calcium, and/or phosphatidyl inositol 3 kinase (PI3K) activation.10,11 Changes in NO levels affect 
the activity of Rho GTPases, key regulators of actin dynamics.12 Coordinated activation of Rho 
GTPases Rac1, RhoA and Cdc42 is required for cell motility.12 Rac1 and Cdc42 mediate focal 
contact/complex formation and polymerization of the actin cytoskeleton at the leading edge of the 
cell, while RhoA controls stability of focal adhesions, stress fibre formation in the main body of 
the cell, and retraction at the rear.12 ADMA activates RhoA and inhibits Rac1 and Cdc42 in 
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pulmonary endothelial cells, leading to inhibition of  spontaneous endothelial cell motility and 
vessel sprouting from aortic rings.7 Rho GTPases also play an essential role in regulating motility 
and angiogenesis in response to growth factors including VEGF, although the requirement for 
individual GTPases appears to depend on the experimental model of angiogenesis.13-16 RhoA is 
required for VEGF-induced angiogenesis in Matrigel plugs13 while Rac1 and Cdc42 but not RhoA 
are important in phorbol ester- and growth-factor- induced angiogenesis in collagen.14 VEGF-
mediated motility requires Rac1 activity,15 but the role of RhoA is controversial.13,15,16 
We hypothesized that ADMA metabolism alters VEGF signalling via its effects on Rho 
GTPases. We show for the first time that ADMA inhibits VEGF-induced endothelial chemotaxis 
and angiogenesis in vitro and in vivo. These effects result from reduced NO signalling and 
inhibition of pSer239VASP and Rac1, important in cell polarization and focal adhesion turnover. 
 
Methods 
Cell culture and treatments  
Primary human umbilical vein endothelial cells (HUVEC, PromoCell) were cultured in 
endothelial growth medium containing 2 % foetal calf serum (FCS) and growth supplements (C-
22010, Promocell). For experiments, the cells were incubated in starvation media containing 1% 
FCS and no growth supplements, or where stated, in L-arginine-free media (PromoCell). ADMA 
(100 µM, Calbiochem, Merck Biosciences, Germany) or NG-Nitro-L-arginine Methyl Ester (L-
NAME, 1 mM, Calbiochem) were added to the medium for 16 hours prior to measurement of cell 
responses. S-nitroso-N-acetylpenicillamine (SNAP, 10 µM, Calbiochem) and human recombinant 
VEGF-165 (25 ng/ml, R&D Systems, Abingdon, UK) were added for the duration of experiments. 
cGMP in cell lysates was measured after treatment with VEGF for 5 minutes, using a commercial 
kit (Biotrak EIA system, RPN226, GE Healthcare, for details please see www.ahajournals.org).  
Adenovirus Construction and Transfection 
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Adenoviral gene transfer was used to over-express DDAH I, RhoAN19, Rac1V12 or Cdc42V12 or 
GFP (transfection control) as described at a multiplicity of infection (MOI) of 200.7 
Analysis of VEGF, VEGFR-2 and cleaved caspase-3 
Soluble human VEGF secretion was quantified using an ELISA kit (QIA51, Calbiochem). 
VEGFR-2, phospho(Tyr1175)-VEGFR-2 and cleaved caspase-3 (Asp175) were measured using 
sandwich ELISA kits (Cell Signaling, New England Biolabs, UK) (for details please see 
www.ahajournals.org). 
RhoA, Rac1 and Cdc42 GTP-binding  
Active RhoA, Rac1 and Cdc42 was measured by affinity precipitation and detected by Western 
blotting as previously described.7 
Cell proliferation and migration  
Migration assays were performed in Transwell dishes and the optical density of 6 random fields 
per filter (triplicate samples) was analysed in Adobe Photoshop. Proliferation was evaluated in 
HUVECs cultured for 2 days in serum-reduced media (1 % FCS) by colorimetric analysis using 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) (Promega, Madison, WI). 
Both assays were validated by manual counting of cells (for details please see 
www.ahajournals.org). 
Focal adhesion analysis  
Focal adhesions were visualised in HUVECs by immunofluorescence using anti-vinculin 
antibodies. Alternatively, live HUVECs were transfected with pDsRed2-N1-Zyxin and seeded in 
optical bottom 96-well plates (for details please see www.ahajournals.org). Images were recorded 
using confocal microscopy and processed using LaserPix software. Cell adhesions in the first 
frame (t = 0) were labelled red, and in the last, were labelled green (pseudocolours, t = 16 
minutes). Protrusions and cell elongation (circularity of a fitted ellipse) were analysed using Image 
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J software (National Institute of Health). Focal adhesion turnover was calculated as the proportion 
of remodelling adhesions (green and red) to constant adhesions (yellow). 
Collagen I in vitro angiogenesis assay 
Cells were seeded onto 24-well plates (5 x 104 per well) pre-coated with PureCol Collagen I 
solution (Nutacon BV, Leimuiden, Netherlands, 2 mg/ml, 300 µl/well). After 24 hours at 37oC, the 
cells were fixed (4 % formaldehyde/PBS) and images from 4 random fields were analysed. Total 
tubule length was calculated using Image J software. 
Basement membrane plug angiogenesis assay  
All experiments were carried out under a Home Office Licence and conducted according to the 
Animal Scientific Procedures Act 1986. Eight week-old wildtype (WT) or DDAHI heterozygous 
(HT) mice3 were injected subcutaneously in both flanks with Cultrex Matrigel basement 
membrane extract (R&D Systems) and 500 ng/ml VEGF,17 and with adenoviruses where indicated 
(4 x 108 plaque forming units / ml Matrigel). After 7 days, mice (n=5) were sacrificed and plugs 
recovered. Histological sections were stained with toluidine blue or antibodies against PECAM-1, 
with DAPI nuclear counter-stain. Angiogenesis was quantified by measuring haemoglobin (Hb) 
content in plugs (for details please see www.ahajournals.org).18 
Retrovirus Construction and Transfection of VASP mutants 
Retroviral constructs encoding human VASP mutants (S239A-VASP and S239D-VASP), were 
inserted into the retroviral vector LXSN. Retroviral stocks were generated by co-transfection with 
pVSVG (Clontech) and pGag-pol (Clontech) into HEK 293T cells and used to infect HUVEC. 
HUVECs stably expressing transgenes were selected with G418 (0.6mg/ml, Sigma). Expression of 
vesicular stomatitis virus glycoprotein (VSVG)–tagged VASP were assessed by Western blotting 
and distribution of pSer239-VASP in HUVECs by immunostaining with mouse monoclonal anti-
pSer239VASP antibody (1:100, Upstate Biotechnology) (for details please see 
www.ahajournals.org).  
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Statistical analysis 
Data are expressed as means ± SEM. Differences among groups were assessed by ANOVA 
followed by post-hoc tests.  A p value <0.05 was taken as statistically significant, n=3, unless 
stated otherwise. 
 
Results 
 
ADMA inhibits VEGF-induced chemotaxis and capillary network formation in vitro. 
Cell migration across Transwell filters in basal conditions (no VEGF) was 4.5 ± 0.5 cells/200 µm2 
in 4-hour assay and increased 2-fold upon the addition of VEGF (p < 0.001, Figure 1A and 1B). 
Exogenous ADMA (100 µM) did not influence basal cell migration, but reduced VEGF response 
to control levels (p < 0.001, Figure 1A and 1B). Lower dose of ADMA (10 µM) had no effect on 
VEGF-mediated migration in basal culture medium, but had a significant inhibitory effect in 
arginine-free culture medium (please see Supplemental Figure I in www.ahajournals.org). Over-
expression of DDAH I restored the chemotactic response towards VEGF in the presence of 
ADMA (Figure 1A and 1B).  
ADMA impairs VEGF-induced angiogenesis in vitro and in vivo. 
To study the effects of ADMA on early stages of VEGF-induced angiogenesis, we used a collagen 
I tube formation assay. Within 24 hours after plating, endothelial cells began to align and form a 
network of tubular structures. While untreated cells showed little evidence of tube formation,  
VEGF induced formation of extensive cell networks, increasing tubulogenesis by 150 %, 
compared to controls (p < 0.001) (Figure 2A, B). ADMA (100 µM) had no effect in basal 
conditions, but reduced VEGF effects by 40 % (p < 0.01, Figure 2A and 2B).  
To investigate the relevance of these observations in vivo, we analysed blood vessel formation in 
Matrigel plugs co-injected with VEGF in DDAH I heterozygous (HT) knockout mice. These mice 
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have raised ADMA levels and show abnormal cardiovascular responses as a result of decreased 
NO signalling.3 VEGF-mediated angiogenesis was severely impaired in DDAH I HT mice 
compared to their wildtype littermates (Figure 2C-E). The presence of blood vessels was 
confirmed by immunofluorescent staining of platelet endothelial cell adhesion molecule-1 
(PECAM-1) (Supplemental Figure II  in www.ahajournals.org). In the absence of VEGF, 
angiogenesis was minimal (Figure 2E). The analysis of haemoglobin levels confirmed that VEGF 
increased blood supply into the plug, and that this was significantly impaired in DDAH I HT mice 
compared to WT (83 % decrease, p < 0.05, Figure 2E and Supplemental Figure II in 
www.ahajournals.org). When VEGF was co-injected with DDAH I adenoviruses into HT mice, 
angiogenesis was enhanced by 197 % (p < 0.05, HT compared to HT + DDAH I, Figure 2E). 
Sustained adenovirus-mediated overexpression of DDAH I was confirmed by Western blotting 
(Supplemental Figure II in www.ahajournals.org).  
 
ADMA effects are mediated by inhibition of NO signalling, and are independent of 
proliferation and apoptosis. 
Since VEGF-mediated motility and angiogenesis require NO, we hypothesized that ADMA effects 
on VEGF-induced angiogenesis may result from inhibition of NO signalling. L-NAME, a NOS 
inhibitor structurally unrelated to methylarginines, inhibited VEGF-mediated chemotaxis to the 
same extent as ADMA (p < 0.001 compared to VEGF), while the NO donor, SNAP significantly 
reduced the effects of ADMA, confirming previously reported role NO in ADMA signalling 
(please see Supplemental Figure III in www.ahajournals.org).7 Intracellular levels of cGMP, a 
downstream effector of NO, were reduced by ADMA in control and VEGF-treated group. DDAH 
did not significantly change cGMP levels in basal conditions but prevented ADMA effects in 
VEGF-treated group (Supplemental Figure III). Changes in cGMP were consistent with previously 
reported changes in nitrite levels in culture media induced by ADMA/DDAH.7,19  
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Endothelial cell proliferation and apoptosis are important in the regulation of angiogenic 
responses. VEGF enhanced endothelial cell proliferation by 34 % (p < 0.001, compared to no 
treatment) but ADMA had no effect on VEGF-mediated proliferation within 48 hours of treatment 
(Supplemental Figures III and IV). It has recently been reported that ADMA is pro-apoptotic.20 
However, while VEGF inhibited cell apoptosis by 27 %, (p < 0.05 compared to no treatment), 
ADMA had no significant effect on apoptosis regardless of the presence of serum, growth factor 
supplements or VEGF (Supplemental Figure III).  
 
ADMA prevents VEGF-induced protrusion formation, focal adhesion turnover and reduces 
cell polarity. 
Inhibition of basal NO production by endothelial cells is associated with decreased motility and 
enlarged focal adhesions, that may result from imbalance in the assembly and disassembly of cell 
attachments.7,21 We hypothesized that ADMA would affect motility by altering focal adhesion 
turnover and distribution. Within one hour after seeding, VEGF promoted formation of 
lamellipodia and peripheral localisation of the focal adhesion protein, vinculin (Figure 3A). 
ADMA reduced peripheral vinculin localisation, while over-expression of DDAH I restored the 
VEGF-induced phenotype (Figure 3A). At later stages of cell spreading, ADMA-treated cells 
showed accumulation of enlarged central focal adhesions, the effect prevented by DDAH (Figure 
3B). To study focal adhesion turnover and protrusion formation in live endothelial cells, the cells 
were transfected to express fluorescently-labelled zyxin, a marker of intermediate/late focal 
adhesions.22 Image analysis of time-lapse confocal images was used to quantify the numbers of 
remodelled focal adhesions and extension/retraction of the cell periphery (please see Supplemental 
Figure IV in www.ahajournals.org). VEGF promoted protrusion formation and focal contact 
remodelling and these effects were significantly inhibited by ADMA and rescued by over-
expression of DDAH I (Figure 3C). Migratory endothelial cells exhibit an elongated, polarized 
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morphology. ADMA prevented cell elongation in both control and VEGF-treated groups (Figure 
3D). 
 
ADMA alters Rho GTPase activation independently of VEGFR-2 activation. 
DDAH II was reported to increase VEGF mRNA in endothelial cell lines.5 However we did not 
observe any measurable changes in VEGF protein expression in HUVECs over-expressing DDAH 
I (data not shown). Since VEGFR-2 mediated signalling is involved in NO dependent endothelial 
cell responses to VEGF,10 we tested whether ADMA could affect VEGFR-2 expression or 
activation. However, neither activity nor expression of VEGFR-2 was affected by either ADMA 
or DDAH I (please see Supplemental Figure V in www.ahajournals.org).  
 
ADMA impairs focal adhesion remodelling and angiogenesis via Rac1. 
The effects of ADMA on VEGF-induced cell motility are likely to be mediated by Rho GTPases, 
important regulators of actin dynamics. ADMA reduced the activity of Rac1 and Cdc42 and 
increased the activity of RhoA in both control and VEGF-treated cells, consistent with its effects 
on pulmonary endothelial cells under basal conditions (Figure 4A, B).7 To further investigate the 
role of Rho GTPases in the effects of ADMA, mutant Rho GTPases were overexpressed by 
adenoviral gene transfer. Constitutively active Rac1 (Rac1V12) prevented inhibition of focal 
adhesion remodelling by ADMA, restoring it to similar levels as VEGF, while constitutively 
active Cdc42 (Cdc42V12) or dominant negative RhoA (RhoAN19) had no effect (Figure 4C). To 
investigate how these observations might relate to angiogenesis in vivo, Matrigel plugs implanted 
in DDAHI HT mice were co-injected with VEGF and Rho GTPase mutants. Rac1V12 
significantly enhanced angiogenesis in DDAH I HT mice, increasing haemoglobin (Hb) content in 
plugs from 32 +/- 26 to 559 +/- 97 (arbitrary units, p < 0.01, Figure 4D), comparable to Hb levels 
in wildtype mice either without (513 +/- 138) or with Rac1V12 (554 +/- 110, Figure 4D). Over-
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expression of RhoAN19 in wildtype mice did not affect VEGF-induced angiogenesis (Fig. 4D), 
while in DDAHI HT knockout mice, some noticeable, though statistically not significant increase 
was observed (p = 0.081, Figure 4D). Over-expression of Cdc42V12 did not influence VEGF-
induced angiogenesis in either wildtype or DDAH I HT knockout mice (Figure 4D). 
ADMA reduces Rac1 activity in pulmonary endothelial cells by decreasing NO/PKG-mediated 
phosphorylation of VASP on Ser239.19 Consistently, ADMA decreased VASP phosphorylation on 
Ser239 in HUVECs treated with VEGF (Figure 5A-D). The upper and lower band of the VASP 
doublet, which is detected by anti-pSer239 antibody is Ser157-phosphorylated and -non-
phosphorylated protein, respectively (Figure 5C).23 Overexpression of mutant of VASP (S239A-
VASP), in which the preferred PKG site is blocked from phosphorylation, inhibited tube 
formation to the same extent as ADMA (Figure 5E). Conversely, a phosphomimetic VASP mutant 
(S239D-VASP) increased tube formation in control cells and cells treated with VEGF and 
ADMA, while nonphosphorylatable VASP mutant (S239A-VASP) decreased tube formation, 
mimicking the effects of ADMA (Fig.5E). The small reduction in tube formation in VEGF-treated 
cells by S239D-VASP compared to untreated vector control, may indicate that dynamic changes 
in VASP phosphorylation are important in this response. Expression of VSVG-VASP mutants was 
confirmed by Western blotting (please see Supplemental Figure V in www.ahajournals.org). 
Overexpression of S239D-VASP increased Rac1 activity in HUVECs (Supplemental Figure V). 
Rac1 can act as an upstream regulator of RhoA activity 24 and therefore we verified its role in 
ADMA-induced effects on RhoA. Overexpression of constitutively activated Rac1 (V12Rac1) 
inhibited RhoA activity in control (untreated) HUVECs but did not abolish RhoA activation by 
ADMA (Supplemental Figure VI in www.ahajournals.org). 
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Discussion 
We show for the first time that a functional DDAH I pathway is required for the 
angiogenic response to VEGF, by regulating Rho GTPase activity. Our in vitro studies indicate 
that ADMA, a substrate for DDAH, impairs endothelial cell responses to VEGF by reducing NO 
dependent chemotaxis and focal adhesion turnover, and abrogating protrusion formation, cell 
polarisation and alignment into capillary networks. ADMA does not affect VEGFR-2 activation or 
expression, but inhibits VEGF-mediated phosphorylation of VASP and activation of Rac1. Focal 
adhesion turnover and angiogenesis in vivo are restored by increasing Rac1 activity, indicating a 
key role for this GTPase as a target in ADMA-induced angiogenic pathologies.  
Angiogenic morphogenesis requires tightly controlled regulation of apoptotic and 
proliferative pathways. In our studies, ADMA did not modulate the effects of VEGF on cell 
proliferation or apoptosis, in contrast to other reports showing anti-proliferative and pro-apoptotic 
effects.20,25 While these discrepancies may result from the use of different cell types and culture 
conditions, it is unlikely that pro-apoptotic effects of ADMA play a role in our system; we 
observed significant short-term effects of ADMA on chemotaxis in vitro, and in vivo substantial 
numbers of endothelial cells accumulated in Matrigel plugs in DDAH I HT mice in spite of high 
tissue and plasma levels of ADMA. DDAH I over-expression also did not induce secretion of 
soluble VEGF, nor did it affect VEGFR-2 activation or expression. These differences are likely to 
be isoform-specific as DDAH II but not DDAH I over-expression induces VEGF mRNA and 
secretion in endothelial cells.5,26 
The dose of ADMA used in our in vitro studies was relatively high (100 µmol/L) while 
lower doses were only effective in media deprived of NOS substrate, L-arginine, confirming the 
involvement of NO signalling. In vivo, heterozygous DDAH I gene deletion in mice increases 
plasma concentration of ADMA 0.5–0.7 µmol/L similar to the levels reported in patients with 
multiple cardiovascular risk factors.3 We found that these mice showed decreased angiogenic 
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responses to VEGF. It is likely that local changes in ADMA concentrations in cells and tissues are 
higher than estimated. Plasma levels of ADMA vary from 0.2-1 µmol/L but tissue levels may 
reach 15 µmol/L.27 Another likely mechanism to explain the effect of low concentrations of 
ADMA in vivo may involve endothelial progenitor cells (EPCs). EPCs are important in 
neoangiogenesis and their mobilization, differentiation, and function are inhibited by plasma 
concentrations of ADMA.25  
Under basal conditions, ADMA has been shown to activate RhoA and inhibit Rac1 in a 
NO/protein kinase G (PKG)-dependent manner,7,19 and we observed similar effects in the presence 
of VEGF. Inhibition of Rac1 by ADMA appears to be particularly deleterious to VEGF-induced 
angiogenic responses. This may reflect a more critical role played by Rac1 in angiogenesis. 
Endothelial-specific deletion of Rac1 is lethal at embryonic day 9.5 due to aberrant angiogenesis, 
and Rac1-deficient endothelial cells fail to form lamellipodia, migrate and undergo angiogenic 
morphogenesis in response to VEGF.28 Further, and reminiscent of the DDAH I HT phenotype,3 
endothelial-specific downregulation of Rac1 results in mild hypertension and impaired 
angiogenesis as a result of decreased NO signalling.29 In support of the role of NO/Rac1 in ADMA 
effects, VEGF-mediated chemotaxis was restored by NO donors and over-expression of 
constitutively activated Rac1 restored focal adhesion remodelling and angiogenesis in DDAH I 
HT knockout mice. The mechanism by which Rac1 regulates angiogenesis is likely to involve 
control of both cell-cell and cell-matrix interactions. Cell-matrix interaction induces dynamic 
cellular protrusions followed by the assembly of endothelial cell aggregates and rudimentary 
cords, requiring Rac1-dependent integration of both actin remodelling and microtubule 
dynamics.30 These dynamic protrusions are thought to be critical in supporting proper cell-cell 
contact and alignment in capillary morphogenesis.30 In line with a Rac1 dependent mechanism 
therefore, we observed that ADMA abrogated lamellipodia formation, cell polarisation and 
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capillary morphogenesis in vitro, while in vivo, endothelial cells were able to invade Matrigel 
plugs in DDAH I HT mice, but failed to align and coalesce into capillary vessels. 
Although Rac1 appears more important in control of VEGF-induced angiogenesis, a role 
of RhoA can not be completely excluded. RhoA inhibition increased remodelling of focal 
adhesions in basal conditions, possibly as an effect of decreased adhesion to the substratum,7 and 
increased blood supply in Matrigel plugs in DDAH I HT knockout mice. RhoA may contribute to 
inhibition of VEGF-mediated angiogenesis by regulating mechanical remodelling of extracellular 
matrix (ECM) and matrix invasion.13 Rac1 reduced RhoA activity in basal conditions but did not 
abolish RhoA activation by ADMA, which suggests that RhoA activity is controlled by two 
different mechanisms. Rac1 is thought to inhibit RhoA by activation of p190 Rho GTPase 
activating protein31 while NO/PKG inhibit RhoA by increasing phosphorylation on Ser188, which 
enhances its interaction with Rho guanine-dissociation inhibitor.32  
VEGFR-2 mediates the effects of VEGF on endothelial motility.11 Interestingly, while 
ADMA did not prevent VEGFR-2 autophosphorylation, it may affect downstream signalling 
pathways in a spatially dependent manner, by preventing VEGFR-2 localisation to 
lamellipodia.33,34 Rac1 regulates lamellipodia formation,12,35,36 and a decrease in its activity may 
prevent proper localisation of activated VEGFR-2. In support of this, we observed reduced 
localisation of VEGFR-2 in lamellipodia in HUVECs treated with ADMA following monolayer 
wounding (Supplemental Figure VII in www.ahajournals.org).  
ADMA inhibits Rac1 activity in pulmonary endothelial cells by decreasing NO/cGMP-
dependent phosphorylation of vasodilator activated phosphoprotein (VASP) on Ser239.19 VASP 
regulates actin dynamics and its localisation and activity is associated with Rac1 activation.23,37 In 
control and VEGF-treated HUVECs, ADMA decreased VASP Ser239 phosphorylation, while 
non-phosphorylatable mutant of VASP mimicked the effects of ADMA on endothelial tube 
formation in vitro, supporting a role upstream of Rac1 in ADMA-induced effects on angiogenesis. 
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In further support of our data, VASP phosphorylation by PKG has recently been shown to enhance 
angiogenesis38 and increase vascular smooth muscle cell matrix invasion (Thomas Renné, 
unpublished observation). Full characterization of the effects of Rac1/RhoA activity imbalance 
induced by ADMA on angiogenesis will require further studies. 
In summary, our observations indicate that the DDAH I/ADMA pathway plays a critical 
role in regulating VEGF-mediated endothelial cell motility and angiogenesis, and that altered NO 
signalling and Rho GTPases activity are central to angiogenic regulation by DDAH I/ADMA. 
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Figure 1. ADMA inhibits VEGF-induced chemotaxis (A, B). Representative images (A) and 
quantitation (B) of transmigrated cells are shown in the absence (white bars) or presence of VEGF 
(black bars), expressed as % of untreated controls. ** p<0.01, *** p<0.001, n=3.  
 
Figure 2. ADMA impairs VEGF-induced angiogenesis in vitro and in vivo. (A) shows 
representative images of tube formation on collagen I and (B) shows quantitation of tube 
formation. (C) shows Matrigel plugs from wildtype (WT) and DDAH I heterozygous knockout 
(HT) mice and (D) plug sections stained with toluidine blue (inset: magnified cross-section of a 
vessel). Arrows point to vessel formation. (E) shows haemoglobin content in plugs (n=5, * 
p<0.05). All plugs contained VEGF except for WT control group shown in (E).  
 
Figure 3. ADMA inhibits polarisation and focal adhesion turnover. Cells were fixed one (A) 
or sixteen hours (B) after plating and focal complexes/adhesions were visualised by 
immunofluorescence. Remodelling index of focal adhesions marked with zyxin-red is shown in 
(C), while changes in cell elongation are shown in (D) (n = 10). * p<0.05, ** p<0.01, comparisons 
with VEGF+ADMA group. 
 
Figure 4. ADMA impairs focal adhesion turnover and angiogenesis by altering Rho GTPase 
activity. (A, B) are representative images of Western blots showing activity changes of RhoA, 
Rac1 and Cdc42 in untreated cells or cells treated with ADMA and VEGF (1 hour), as indicated. 
Densitometric analysis of the blots is shown below (n=3), * p<0.05. (C) and (D) show the effects 
of mutant Rho GTPases on focal adhesion remodelling and the in vivo angiogenesis, respectively. 
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Mutant RhoGTPases were overexpressed via adenoviral gene transfer as described in Materials 
and Methods (n=5). In (D) white bars show measurements in wildtype (WT) mice, and black bars 
in DDAH heterozygous knockout (HT) mice. * p<0.05, ** p<0.01 
 
Figure 5. ADMA inhibits angiogenesis by inhibiting VASP activation. After treatment with 
VEGF (10 minutes), pSer239VASP was assessed by immunofluorescent staining (A), with 
fluorescence intensity shown in (B) * p< 0.05, ** p< 0.01, (n = 5). Changes in VASP 
phosphorylation on Ser239 were confirmed by Western blotting (C), with densitometric analysis 
shown in (D), (n=2). In (E), tube formation was assessed in cells expressing S239D-VASP and 
S239A-VASP (black bars). Uninfected (white bars) and empty vector controls (grey bars) are also 
shown. ** p< 0.01, comparisons between empty vector group and VASP mutants groups.  
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